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Abstract: Acute myeloid leukemia (AML) is a heterogeneous disease, and this heterogeneity includes
the capacity of constitutive release of extracellular soluble mediators by AML cells. We investigated
whether this capacity is associated with molecular genetic abnormalities, and we compared the
proteomic profiles of AML cells with high and low release. AML cells were derived from 71 consecutive
patients that showed an expected frequency of cytogenetic and molecular genetic abnormalities.
The constitutive extracellular release of 34 soluble mediators (CCL and CXCL chemokines, interleukins,
proteases, and protease regulators) was investigated for an unselected subset of 62 patients, and they
could be classified into high/intermediate/low release subsets based on their general capacity of
constitutive secretion. FLT3-ITD was more frequent among patients with high constitutive mediator
release, but our present study showed no additional associations between the capacity of constitutive
release and 53 other molecular genetic abnormalities. We compared the proteomic profiles of two
contrasting patient subsets showing either generally high or low constitutive release. A network
analysis among cells with high release levels demonstrated high expression of intracellular proteins
interacting with integrins, RAC1, and SYK signaling. In contrast, cells with low release showed high
expression of several transcriptional regulators. We conclude that AML cell capacity of constitutive
mediator release is characterized by different expression of potential intracellular therapeutic targets.
Keywords: acute myeloid leukemia; gene mutations; differentiation; cytokines; proteomic profile;
integrin; RAC1; SYK
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by
clonal proliferation of a hierarchically organized leukemia cell population that arises from hematopoietic
progenitors in the bone marrow [1–3]. AML is distinguished from other related blood disorders by
the presence of at least 20% myeloblasts in the bone marrow [1–3]. However, despite this common
characteristic, AML is very heterogeneous [1], and patients differ, for example, with regard to genetic
abnormalities [4–7], transcriptional [8] and cell cycle regulation [9], autocrine and paracrine growth
regulation [10–13], as well as the cellular metabolomic [14] and proteomic profiles [15–17]. This cell
population heterogeneity is also reflected in the biological characteristics of AML stem cells [8,10].
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Most relapses occur within 2–3 years after diagnosis and the overall five-year leukemia-free survival
for younger AML patients able to receive intensive chemotherapy possibly combined with stem cell
transplantation is only 45–50%, and a major cause of death is chemoresistant AML relapse thought to
originate from remaining AML or preleukemic cells that recapitulate disease development [18–21]. Cure is
not possible for the large group of elderly/unfit patients who cannot receive such intensive therapy due
to an unacceptable high risk of severe treatment-related morbidity or treatment-related mortality [2].
Thus, there is a need for identification of new therapeutic targets and development of new therapeutic
strategies that are more efficient and better tolerated [22]. Targeting of the bidirectional communication
between AML cells and their neighboring leukemia-supporting stromal cells is a possible approach [23–28].
In a previous study investigating another patient cohort, we described that high constitutive mediator
release is associated with better long-term overall survival compared with low constitutive release [29].
The aims of the present study were, therefore, to characterize the in vitro secretome of primary human
AML cells, to investigate possible associations between the capacity of constitutive mediator secretion
and molecular genetic abnormalities, and to compare the proteomic profiles for primary AML cells with
generally high and low capacity of releasing extracellular soluble mediators.
2. Materials and Methods
2.1. AML Patients and Preparation of Primary AML Cells
The study was approved by the Regional Ethics Committee (REK) (REK III 060.02, 10th of June
2002; REK Vest 215.03, 12th of March 04; REK III 231.06, 15th of March 2007; REK Vest 2013/634,
19th of March 2013; REK Vest 2015/1410, 19th of June 2015), The Norwegian Data Protection Authority
02/1118-5, 22 October 2002, and The Norwegian Ministry of Health 03/05340 HRA/ASD, 16 February
2004. All samples were collected after written informed consent.
The study population included 71 consecutive AML patients with high peripheral blood blast
counts (>5 × 109/L) and a high percentage of leukemic blasts among peripheral blood leukocytes
(Table 1). Highly enriched AML cell populations (at least 95% leukemic blasts) could thereby be
prepared by density gradient separation alone (Lymphoprep, Axis-Shield, Oslo, Norway). The cells
were stored in liquid nitrogen until used in the experiments [30].
Table 1. The clinical and biological characteristics of the 71 acute myeloid leukemia (AML) patients
included in the study.
Age and gender Etiology
Median (years) 64 Previous chemo-radiotherapy 1
Range (years) 18–90 CML 1
Females 31 Li–Fraumeni’s syndrome 1




FAB1 classification Cytogenetic abnormalities3
M0/1 26 Adverse 17
M2 14 Favorable 5
M4/5 22 Intermediate 43
M6 1 Normal 404




1 The French–American–British classification. 2 The percentage of positive cells in flow cytometric analysis. 3 The
European Leukemia Net classification was used [2]. 4 The 43 patients classified as intermediate cytogenetics included
40 patients with normal karyotype. Abbreviations: CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome.
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2.2. Mutation Profiling, Flow Cytometric Analyses, and Analysis of Global Gene Expression Profiles
Submicroscopic mutation profiling of 54 genes frequently mutated in AML was done by using
the Illumina TruSight Myeloid Gene Panel and sequenced using the MiSeq system and reagent kit
v3 (all from Illumina, San Diego, CA, USA). A detailed description of the methodology and the 54
genes is given in a previous publication [31]. Fragment analysis of FLT3 exon 14–15, NPM1 exon 12,
and sequencing of CEBPA were performed as described previously [32].
Immunophenotyping was performed as a part of the standard diagnostic workup using freshly
isolated cells [2], and analyses were performed by multiparametric flow cytometry (BD FACS Canto;
Franklin Lakes, NJ, USA).
Our methods for analysis of global mRNA profiles have been described previously [31]. All these
analyses were performed using the Illumina iScan Reader and based upon fluorescence detection
of biotin-labeled cRNA. For each sample, 300 ng of total RNA was reversely transcribed, amplified,
and biotin-16-UTP-labeled (Illumina TotalPrep RNA Amplification Kit; Applied Biosystems/Ambion;
San Diego, CA, USA). The amount and quality of the biotin-labeled cRNA was controlled by the
NanoDrop spectrophotometer and Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.; Santa Clara,
CA, USA). Biotin-labeled cRNA (750 ng) was hybridized to the HumanHT-12 V4 Expression BeadChip.
The Human HT-12 V4 BeadChip targets 47,231 probes that are mainly derived from genes in the NCBI
RefSeq database (Release 38). Data from the array scanning were investigated in GenomeStudio and
J-Express 2012. All arrays within each experiment were quantile normalized before being compiled
into an expression profile data matrix.
2.3. Analysis of Constitutive Mediator Release by Primary Human AML Cells
The studies of constitutive mediator release included a consecutive subset of 46 patients from the
original study population (see Section 2.1 and Table 1). AML cells (1 × 106/mL) were cultured for 48 h
in Stem Span SFEMTM medium in flat-bottomed 24-well (2 mL/well) culture plates (Nunc Micro-Well;
Sigma-Aldrich, Saint-Louis, MO, USA) before supernatants were collected and stored at −80 ◦C until
analyzed. The levels of the following 34 mediators were determined by Luminex analyses (R&D Systems;
Minnesota, MN, USA) or enzyme-linked immunosorbent assays (ELISA) (R&D Systems; Minnesota,
MN, USA): (i) the chemokines CCL2-5 and CXCL1/2/5/8/10/11; (ii) the interleukins IL-1β/1RA/6/10/33;
(iii) the matrix metalloproteinases MMP-1/2/9 together with the protease/protease regulators tissue
inhibitor of metalloproteinases 1 (TIMP-1), Cystatin B and C, polymorphonuclear (PMN) elastase,
serpin C1 and E, and CD147, plasminogen activator (PA), and complement factor D (CFD); (iv) the
immunomodulatory tumor necrosis factor-α (TNF); (v) the growth factors granulocyte-macrophage
colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), heparin-binding EGF-like
growth factor (HB-EGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor
(VEGF); and (vi) the soluble angiopoietin-1 receptor tyrosine kinase with immunoglobulin-like and
EGF-like domain 2 (Tie-2).
2.4. Proteomic Profiling: Selection of Patients, Sample Preparation, and Proteomic Analysis
The present study is based on mutational analysis of the leukemic cells for 71 consecutive and
thereby unselected AML patients with a high number and/or percentage of AML blasts in the peripheral
blood (Table 2). This selection based on the peripheral blood blast level (see Section 2.1) was used
to reduce the risk of inducing molecular alterations in the leukemia cells due to more extensive
separation procedures. The karyotyping (Table 1) as well as the mutational analyses showed an
expected frequency of both cytogenetic and molecular genetic abnormalities, suggesting that despite
the separation-dependent selection of patients, they are representative for AML in general. Constitutive
cytokine release was investigated for a consecutive and thereby unselected subset of 46 patients from
the original study population. Global proteomic profiling of enriched AML cells was performed
for 16 of the 46 patients included in the constitutive release study; and these 16 patients represent
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all patients in the secretomic cohort completing intensive antileukemic treatment with induction
chemotherapy followed by either 2–4 consolidation cycles or allogeneic stem cell transplantation as
the final consolidation. Thus, they represent an unselected subset of relatively young and fit patients
(Tables S1,S2).
Table 2. An overview of the mutational landscape of 71 consecutive AML patients. The table presents
the main classification and the number of mutations. For each main class the term total group refers to
the total number of mutations in this class (first number) together with the number of patients with
mutations belonging to this main class (second number). Those mutations that should be included as
a part of the prognostic evaluation in routine clinical practice are marked with arrows (↑ increased
survival; ↓ decreased survival) [2].








Total group 20–20 EZH2 3
Signaling
↓FLT3-ITD 20 GATA2 4
FLT3-TKD 8 KDM6A 1




KIT 1 ↑CEBPA 8
KRAS 5 ↓RUNX1 13






Total group 49–42 BCORL1 4
Tumor
suppressors
CDKN2A 1 SF3B1 2
CUX1 1 SRSF2 8
IKZF1 7 ZRSB2 1




WT1 5 SMC1A 1
Total group 24–21 STAG2 8
DNA
methylation




IDH2 11 NOTCH1 2
KMT2A/MLL 2 SETBP1 1
TET2 12 Total group 6–5
Total group 49–39
We followed the step-by-step procedure published previously for proteomic sample preparation
and analysis of primary AML cells [15], except for the following two modifications: the 20 µg cell
lysates were analyzed as label-free samples in contrast to being spiked with an internal standard,
and no peptide fractionation was performed. The samples were analyzed on a QExactive HF Orbitrap
mass spectrometer (Thermo Fisher Scientific; Waltham, MA, USA) coupled to an Ultimate 3000 Rapid
Separation LC system (Thermo Fisher Scientific) [33,34]. The raw LC–MS files were searched against
a concatenated reverse-decoy Swiss-Prot Homo sapiens fasta file (downloaded 05.03.18, containing
42,352 entries) in MaxQuant version 1.6.1.0 [35,36].
2.5. Bioinformatical and Statistical Analyses and Presentation of the Data
All statistical analyses were performed in GraphPad Prism 5 (GraphPad Software, Inc., San Diego,
CA, USA). Unless otherwise stated, p-values <0.05 were regarded as statistically significant. The Fisher’s
Exact test was used to compare different groups (two-tailed p-values). Bioinformatical analyses were
performed using the J-Express 2009 analysis suite (MolMine AS, Bergen, Norway) [37]. Concentrations
were then median normalized and transformed to logarithmic values before differences were analyzed.
Unsupervised hierarchical clustering was performed with Euclidian correlation and complete distance
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measure for all analyses in J-Express. The Panther classification system (version PANTHER14.0) was
used to identify distinct functional classes [38].
The proteomics data processing of the raw data (i.e., filtering for reverse hits, contaminants and
proteins only identified by site, and log2 transformation of label-free quantification (LFQ) intensities),
and statistical analysis of two groups using Welch’s t-test was performed in Perseus version 1.6.1.1. [39].
Furthermore, Z-statistics were used to find the proteins with the most abundant fold changes (FCs), i.e.,
the proteins with highest or lowest FC when comparing the high-release with the low-release group and
calculating the FCs from the median log2 intensity per group as described by others [40]. Unsupervised
hierarchical clustering was performed with Euclidian correlation and complete distance measure for
all analyses in J-Express [37], and gene ontology analysis in DAVID version 6.8 [41]. Gene ontology
(GO) terms with false discovery rate (FDR) < 0.05, the number of proteins associated to the term,
and the fold enrichment were presented. The significantly different proteins were imported to the
STRING database version 11.0 [42] to obtain protein–protein interaction networks, using experiments
and databases as interaction sources at highest confidence (0.9). The networks were imported and
visualized in Cytoscape version 3.3.0 [43]. Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/) was
used to create Venn diagrams.
To summarize, due to the previously described AML heterogeneity and the fact that we sometimes
have unequal numbers of quantified values of a protein in the two groups, we assumed an unequal
variation in the groups and first applied the Welch t-test to identify proteins with significantly (p < 0.05)
different mean tests. Thereafter we used Z-statistics as an additional test to identify those proteins
with the most extreme/significant fold changes (fold change defined as the median intensity for
high-release patients relative to the median intensity for low-release patients; the intensities were then
log2-transformed).
3. Results
3.1. The Genetic Heterogeneity of AML Patients: TP53 Mutations are Associated with High-Risk Karyotypes
and NPM1 Mutations are Associated with Mutations in DNA Methylation Genes
We analyzed the submicroscopic mutational profile for all 71 patients. The profile included 54
frequent mutated genes in myeloid malignancies, 37 of them carried non-benign mutations in our
patients (Figure 1). At least one mutation was detected for 69 of the 71 patients, and one of patients
without detected mutations had a balanced translocation. The median number of mutations per patient
was 3.5 (range 0–7). The most frequently detected mutations were NPM1 exon 12 insertion and the
FLT3-ITD mutation (20 patients for each), followed by mutations in the DNMT3A (19), TET2 (13),
and RUNX1 (13) genes (Figure S1).
We used the same (and now generally accepted) classification of AML-associated mutations
in our present study as was used in two large previous studies, including 1540 and 200 patients,
respectively [6,7]. The following mutations were detected in our patients: (i) NPM1 insertion
(detected in 20 out of the 71 patients), (ii) mutations causing activation of intracellular signaling
(9 genes, 42 patients), (iii) mutated tumor suppressor genes (8 genes, 21 patients), (iv) mutations in
genes involved in DNA methylation (5 genes, 39 patients) or (v) chromatin modification (3 genes,
15 patients), (vi) mutations in genes encoding myeloid transcription factors (3 genes, 20 patients), (vii)
mutated genes important for the spliceosome (5 genes, 15 patients), (vii) mutated genes encoding
cohesion proteins (3 genes, 9 patients), and (viii) the three genes CSF3R, NOTCH1, and SETBP1 that
were mutated in 5 patients (Table 2). The median number of different class mutations per patient was
2.5 (range 0–5); 24% of the patients had mutations from two different main classes and 34% from three
main classes of mutations (Table S1).
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highly significant association between NPM1 and DNA methylation gene mutations (Fisher’s Exact 
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Figure 1. The total genomic profile and organization of mutations into defined categories; an overview
of the data for the 71 AML patients included in our study. The figure shows the somatic mutations
identified from a 54 gene mutation panel, the mutations being classified as described previously [6,7].
A majority of 69 patients had at least one detectable mutation. Risk classification of the karyotypes,
morphological signs of differentiation (i.e., FAB-classification), etiology, age, and gender are presented
in the right part of the figure. The patients selected for proteomic analyses are indexed with black in
the left part of the figure.
We compared the mutational status with karyotype, French–American–British (FAB) classification
(i.e., morphological differentiation), de novo versus secondary leukemia, age, and gender (Figure 1);
these statistical analyses are summarized in Table S3. Firstly, we observed a highly significant association
between NPM1 and DNA methylation gene mutations (Fisher’s Exact test, p = 0.0015), whereas the
association between FLT3-ITD and NPM1 mutations did not reach significance. Secondly, there was a
negative association between NPM1 and myeloid transcription factor mutations (Fisher’s Exact test,
p = 0.0001), and also between NPM1 and chromatin modifier mutations that occurred together only
for two patients. Thirdly, all patients with TP53 mutations had high-risk cytogenetic abnormalities
(Fisher’s Exact test, p < 0.0001). Fourthly, NPM1 mutations were associated with morphological signs
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of differentiation, i.e., FAB classification M2/M4/M5/M6 (Fisher’s Exact test, p = 0.0233). Finally, even in
this relatively small patient cohort, we observed that no patients with TET2 mutations (13 patients)
had IDH mutation (5 patients); this inverse correlation has been described in previous cohorts [6],
but did not reach statistical significance in our smaller cohort. We did not detect any significant
associations between individual mutation or mutational main classes and age, gender, or AML etiology
(de novo/secondary). A trend toward higher number of identified mutations in patients >65 years was
detected, (median 4 mutations >65 years, and median 3 mutations <65 years), although did not reach
statistical significance in this patient cohort. To summarize, the frequencies of individual mutations
and the various associations are similar to what has been described previously [7,44]; the observations
thus suggest that our patient cohort of consecutive patients with relatively high peripheral blood blast
counts is representative for AML in general.
3.2. Expression of Molecular Differentiation Markers by Primary AML Cells: The Expression of the CD34 Stem
Cell Markers Differs between Mutational Subsets
The AML cell expression of eight common differentiation markers (CD13, CD14, CD15, CD33,
CD34, CD45, CD117, and HLA-DR) was available for 62 unselected AML patients. We first did an
unsupervised hierarchical cluster analysis based on this expression profile (Figure S2). We could then
identify four main patient subsets, but no single mutation or mutational class showed significant
associations with any of the four main patient clusters.
We investigated whether there were any significant correlations between the CD34 stem cell
marker and any of the other differentiation markers, but no significant associations were then detected.
We finally investigated whether any of the mutations that are used as prognostic markers in
routine clinical practice [2] showed significant correlations with the expression of single differentiation
markers. These statistical analyses are summarized in Table S3. Firstly, NPM1 mutations showed a
significant correlation with CD33 expression (Fisher’s Exact test, p = 0.0107) and a negative association
with CD34 expression (Fisher’s Exact test, p < 0.0001). These NPM1 associations are similar to the
observations in a previous large study of 184 unselected patients [45], and they are consistent with the
observation that NPM1 mutations are frequently associated with morphological signs of differentiation
(see above). Secondly, neither FLT3-ITD nor DNMT3A mutations showed any association with
CD34 expression. NPM1 mutations are frequently combined with FLT3-ITD and DNA-methylation
mutations [6], but only the negative NPM1 association reached significance in our relatively small
cohort. Thirdly, patients with mutations in chromatin modifier genes showed an increased frequency
of CD34 expression by their AML cells (Fisher’s Exact test p = 0.0159). We detected the combination of
NPM1 and chromatin modifier mutations for only two patients, and this was similar to the observations
in previous studies [7]. Thus, these mutational subsets also differ in their expression of differentiation
markers, especially CD34 expression.
3.3. AML Patients Can Be Subclassified Based on Their Constitutive Release of Extracellular Mediators,
but this Capacity Shows no Association with the Mutational Profile
Primary AML cells from 46 of the patients were available for additional studies of constitutive
cytokine release during in vitro culture. This patient subset represents a constitutive and thereby
unselected subset among the 71 patients included in our present study. We investigated the
constitutive release of 34 soluble mediators, including several cytokines (interleukins, CCL
and CXCL chemokines, immunoregulatory cytokines, growth factors), proteases, and protease
regulators/inhibitors. A clustering analysis identified a subset of patients with generally high
constitutive mediator release; the other patients showed generally low or intermediate release (Figure 2).
Neither any single mutation nor mutational main class differed significantly when comparing the three
patient subsets identified in this clustering analysis.
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3.4. Comparison of Global Gene Expression Profiles for Patients with Generally High and Low Constitutive
Release of Extracellular Mediators
We have previously described differences in global gene expression profiles between AML cells
with generally high and low constitutive mediator release [46]. We performed a similar comparison for
the patients included in the present studies based on the differentially expressed genes, and we could
then identify two main patient subsets based on this expression (d-score >3.5; 149 genes identified).
However, these two subsets did not differ significantly with regard to the distribution of single
mutations or the overall mutational profiles of the AML cell populations (Figure S3).
3.5. Comparison of Proteomic Profiles for AML Cell Populations Showing Generally High and Low Constitutive
Release of Extracellular Mediators
Our proteomic analyses identified 5852 proteins, but 5586 proteins were left after leaving out
protein contaminants, reverse hits, and proteins only identified by site. Our further analyses were based
on 4350 proteins that could be detected in at least five patients for each of the two compared groups.
A significant difference (p < 0.05) in protein abundance between the two groups was detected for 256 of
these proteins (182 proteins increased in patients showing high constitutive release, 74 proteins being
increased in the others), i.e., determined by Welch’s t-test and Z-statistics (a list of selected proteins are
described more in detail in Table S4 and the complete list of all 256 proteins is given in Table S5).
We first performed an unsupervised hierarchical cluster analysis (Euclidean measure, and complete
distance) based on the 256 differentially expressed proteins (Figure 3). Our analysis identified two
main clusters/subsets of patients corresponding to patients with generally high and low constitutive
release by their AML cells; only one of the high release patients clustered as an outlier. Furthermore,
we performed GO term overrepresentation analyses based on the 256 differentially abundant proteins.
The analysis of those proteins showing increased expression (n = 74) in patients with low constitutive
mediator release and returned significantly increased GO terms, which reflected an altered regulation
of nuclear functions/transcription/RNA metabolism (Table 3 and Table S4). It can be seen that a major
part of these genes are important for transcriptional regulation/RNA expression/RNA metabolism.
We then analyzed those proteins showing increased expression in AML cells with high constitutive
cytokine release; the most significant GO-terms are listed in Table 4. When analyzing the proteins with
regard to cell compartment the four largest terms (extracellular exosomes, cytosol, membrane, and
cytoplasm) were only partly overlapping with regard to individual proteins and included 153 of the
182 proteins that were significantly increased in high-release AML cells (Figure 4). These four GO terms
reflect cytoplasmic/cytosolic structures/functions together with the terms actin filament and phagocytic
vesicle membrane. One of the terms reflects metabolic functions (NADPH oxidase complex), whereas
the two last terms reflect cell surface functions/cellular communication (focal adhesion, membrane
rafts). Analysis of biological processes and molecular functions included several relatively small GO
terms that also reflect intracellular signaling, protein interactions, or cell surface receptor signaling
(Table 4). Table S4 gives a more detailed description of those proteins that were identified both in
the GO term analyses (Table 4, Figure 4) and in the network analysis (Figure 5; proteins in the large
network to the left in the figure with increased levels in high-secreting cells).
The proteins with increased expression in patients with generally high constitutive release are
presented in Figure 4 (all proteins included in the GO-terms GO:0070062—extracellular exosome,
GO:0005829—cytosol, GO:0016020—membrane, or GO:0005737—cytoplasm); Table 3 (classification of
proteins showing p < 0.01); Table S4 (description of proteins from Table 3 with p < 0.01); and Table
S5 (the complete list of all 256 differentially expressed proteins). These more detailed analyses and
classifications of individual proteins from Table 3 and Table S4 also show that AML cells showing
generally high or low constitutive release of extracellular mediators differ especially with regard to
transcriptional regulation, cell surface molecular profile, intracellular signaling, intracellular trafficking,
and cell adhesion/migration.
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included in the proteomic studies belonged to the cluster characterized by generally high constitutive mediator release and the eight others showed low/intermediate
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regard to clinical or biological characteristics either (right panel).
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Table 3. Differentially expressed proteins in primary AML cell populations with high (left) and low (high) constitutive release of extracellular soluble mediators.
The mediators are classified based on their main functional characteristics. The information is based on the Gene database and selected references from the
PubMed database (Table S4). The proteins being increased in high-secreting AML cells are those proteins that were both included in the gene ontology (GO) terms
GO:0070062—extracellular exosome, GO:0005829—cytosol, GO:0016020—membrane, and GO:0005737—cytoplasm (Figure 4), and also in the main interacting
protein network in the left part of Figure 5 (Table S4). The proteins being increased in the low-secreting AML cells are those proteins included the GO terms
GO:0000790—nuclear chromatin and GO:0005736—DNA-directed RNA polymerase I complex (Table 4).
Main Classification Increased Protein Levels in Cells with High Constitutive Release Increased Protein Levels in Cells with LowConstitutive Release
Nucleosome MBD3
Chromatin, histone, transcription, RNA TOLLIP, NFKB1 HIF0, HISTIH2AJ, MTA1, SMARCE1, MEN1, MBD3,POLR1E, CLPX, POLR1A, POLR1B
DNA repair CLPX, JUND, POG2
Oncogene CBL, DBNL
Cell cycle regulation IL16
Intracellular signaling SYK, HCLS1, AKAP1, TLR2, TOLLIP, AGTRAP, ANXA2, CECR1, INPP5D,LPKN, IKBKB, TBK1
Tyrosine kinase SYK, HCLS1, FGR, PKN1
SRC tyrosine kinases HCLS1, FGR, HCK,
PI3K-Akt-mTOR NCF4
RAC1 RAC1, NCF4, RHOT1, ARHGEF1, PKN1, RHOG, ARHGAP30, PREX1,GMIP, DOK2, AKAP1
GTPase DNM2, ARHGEF1, PKN1, RHOG, ARHGAP30, PREX1, GMIP, AKAP1,ARHGAP, RAB27A
G-protein coupled receptors ARRB2, ARHGEF1, PREX1, GRK6
Phagocytosis CYBA, NCF2, NCF4, ELMO2
Protein degradation CBL, SERPINA1
Intracellular trafficking VAMP3, DNM2, PICALM, SNX18, ARAP1, ARAP1, TOLLIP, AP1G2,S100A10, S100A4, TOM1, SDCDP, DNAJC13, EPN1, APHGAP, RAB27A
Microtubule, cytoskeleton, structure DNM2, EPN1, SH3KBP1, PKN1, RHOG, AHNAK, SDCDP, S100A4,CKAP4, FAM49B
Cell migration PLXNB2, HCK, DNM2, RHOG, ELMO2, AHNAK
Mitochondria, metabolism FAM49B, FTL, IMPDH1, PDXK CLPX
Lysosomes CTSH, CTSS, CTSZ, LYZ, PSAP
Cell metabolism, NADP HCK, NCF4
Cytokinesis FMNL1
Extracellular matrix, cell adhesion EPN1, SH3KBP1
Extracellular mediators IL16, TLR2, TOLLIP
Cell surface molecules ITGAL, ITGAM. ITGB2, SYK, LILRB2, PKN1, LPXN
Integrins ITGAL, ITGAM. ITGB2, SYK, FGR, LPXN
Viability, apoptosis SH3KBP1, PKN1, ARAP1, TLR2
AML CBL, PICALM
Differentiation MNDA, NCF1, CECR1
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Table 4. Significant GO-terms (i.e., FDR < 0.05) for proteins showing significantly increased levels in AML patients with intermediate/low and high constitutive
mediator release.
Low constitutive mediator release; list of significant GO-terms Protein number Fold enrichment FDR
Cell compartment GO:0005654—nucleoplasm 31 2.8 2.3 × 10–5
GO:0000790—nuclear chromatin 8 11 0.0099
GO:0005736—DNA-directed RNA polymerase I complex 4 80 0.017
Molecular function GO:0003713—transcription coactivator activity 9 8.5 0.011
GO:0001054—RNA polymerase I activity 4 78 0.018
High constitutive mediator release; list of significant GO-terms
Biological processes GO:0006954—inflammatory response 19 5.0 6.5 × 10–5
GO:0045087—innate immune response 20 4.7 8.3 × 10–5
GO:0048010—vascular endothelial growth factor receptor
signaling pathway 9 13 8.6 × 10
–4
GO:0007229—integrin-mediated signaling pathway 10 10 9.4 × 10–4
GO:0031623—receptor internalization 7 16 0.0062
GO:0007165—signal transduction 29 2.5 0.015
GO:0098609—cell–cell adhesion 13 4.8 0.026
Cell compartment GO:0070062—extracellular exosome 73 2.7 1.4 × 10–13
GO:0005829—cytosol 79 2.5 5.7 × 10–13
GO:0016020—membrane 48 2.3 7.8 × 10–5
GO:0043020—NADPH oxidase complex 5 43 0.0048
GO:0005737—cytoplasm 78 1.6 0.010
GO:0030670—phagocytic vesicle membrane 7 12 0.026
GO:0005925—focal adhesion 15 4.0 0.03
GO:0045121—membrane raft 11 5.6 0.038
GO:0005884—actin filament 7 11 0.046
Molecular function GO:0005515—protein binding 129 1.4 5.8 × 10–6
GO:0017124—SH3 domain binding 11 8.9 5.8 × 10–4
GO:0035325—Toll-like receptor binding 4 96 0.0058
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We finally did a molecular network analysis based on the 256 differentially abundant proteins,
and Figure 5 shows all molecular connections identified in this analysis (those molecules without any
connections are left out). A total of 129 proteins were included in various networks; most of them
appeared in a large network linked to the nodes spleen tyrosine kinase (SYK), NCF4 (a cytosolic regulator
of superoxide-producing NADPH-oxidase), ARRB2 (regulator of G-protein-coupled receptor activity),
ACTR3 (a major constituent of the ARP2/3 complex located at the cell surface and being essential
for cell motility), and RAC1 (a GTPase belonging to the RAS superfamily of small GTP-binding
proteins). Our overrepresentation analysis showed that exosomal proteins as well as proteins
important for intracellular trafficking were differentially expressed; both these groups are important
for communication from the leukemic cells to neighboring AML supporting stromal cells [47]. On the
other hand, our network analysis showed that these AML cells had increased levels of several members
of a signaling pathway, including cell surface integrins (αLβ2, αMβ2) known to mediate downstream
signaling involving SYK and SRC kinase family members (FGR, HCK) [48–51]. Toll like receptor (TLR)
2 together with its downstream NFκB complex are also linked to this network [49]. Taken together
these observations suggest that high constitutive extracellular release of soluble mediators is only a part
of a more complex cellular phenotype that is characterized by differences in the bidirectional crosstalk
between the leukemic cells and their neighboring AML-supporting cells. This bidirectional crosstalk
involves cytokine-mediated signaling directed from the AML cells to the stromal cells. At the same
time the stromal cells may influence the AML cells through soluble mediators or cell–cell contact with
ligation of cell surface molecules, followed by downstream signaling (involving kinases and G-protein
initiated signaling), and finally NFκB mediated modulation of cytokine/chemokine expression [48–52].
Finally, this crosstalk involves integrins that can mediate both inside–out and outside–in effects [48].
4. Discussion
AML is a heterogeneous disease, and this can also be seen from our present studies of primary
human AML cells derived from a cohort of consecutive patients. In this study we focused on the
molecular genetic abnormalities and the proteomic profiles of the leukemic cells [53]. Both the number
and the nature of the molecular genetic abnormalities differed between the patients (number of
detected mutations per patients 0–7, median 3.5 mutations). The frequencies of the various mutations
were comparable to previous studies [6,7], NPM1 mutations were associated with molecular and
morphological signs of differentiation [45], and TP53 mutations were associated with adverse
karyotypes [54]. Taken together, these observations suggest that we investigated a representative
AML patient population, even though we selected patients with relatively high peripheral blood blast
counts/percentages.
In the present study, we included a group of consecutive and thereby unselected AML patients
with a high percentage of leukemic blasts in peripheral blood. We used this selection of patients so
that highly enriched AML cell populations could be prepared by density gradient separation alone;
the risk of inducing molecular and/or functional alterations in the AML patients by more extensive
cell separation procedures was thereby avoided [55]. Our results may therefore be representative
only for this selected subset of patients, but several observations suggest that they possibly are
representative for AML in general. Firstly, our patients showed an expected fraction of secondary
versus de novo AML [56,57]. Secondly, as previously described in detail patients selected according to
these criteria show a similar distribution of cytogenetic abnormalities as AML patients in general [30].
Thirdly, our present study shows that the distribution of various molecular genetic abnormalities is
also similar to AML in general [6,7,44,58]. Finally, we have described in detail the selection of the 16
AML patients included in our proteomic studies (see Section 3.5), and they should then be regarded as
representative for relatively young AML patients.
Extensive separation procedures will influence the functional characteristics of primary human
AML cells, and one would expect that in vitro incubation in culture medium would have similar effects.
However, previous studies have shown that the characteristics of even long-term cultured primary
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human AML cells are associated with patient survival [59], an observation suggesting that even in vitro
cultured cells will reflect functional characteristics of clinical relevance.
Distinct immunophenotype profiles may be associated with specific mutations, and search for
immunophenotype-based screening approaches have therefore been suggested [60,61]. We investigated
the immunophenotype profiles of individual patients based on the expression of eight differentiation
markers commonly used for classification of myeloid cells. We identified four different main
clusters/patient subsets based on this profiling, but no single mutation or mutation main classes
showed significant associations to any of these profiles. However, associations between mutations and
single differentiation markers were observed, especially expression of the CD34 stem cell marker that
was negatively associated with NPM1 mutations as well as FLT3-ITD and DNMT3 mutations, whereas
chromatin modifier mutations were positively associated with CD34 expression. Such associations
have also been described previously [45,62]. A possible explanation for this is that single mutations
may have a major impact on the expression of single or related markers, whereas the overall mutational
profile has a major impact on the overall differentiation profile.
In previous studies we showed that the constitutive release of a wide range of soluble mediators
by primary AML cells varied considerably between patients, and a subset of patients then showed
a generally high release compared with other patients that either showed intermediate or low
release [11,52]. This capacity of constitutive mediator release was tested in a highly standardized
in vitro model. We investigated the constitutive release for a consecutive subset of our patients,
and again we found that a subset of patients showed generally higher release of most mediators
compared with the other patients. We then selected those samples that were derived before the first time
of diagnosis for all relatively young patients that completed intensive chemotherapy. We compared
the proteomic profiles of the primary AML cells for eight patients showing high and another group of
eight patients showing generally lower mediator release.
Several proteins were differentially expressed when comparing patients with generally high and
low constitutive cytokine release. The high release patients showed high expression, especially of
proteins involved in intracellular signaling, intracellular transport/trafficking and communication
between cells (soluble mediators, exosomes, cell surface molecules, and intracellular mediators
downstream to cell surface receptors). We did not identify any of the soluble mediators when analyzing
differentially abundant cell proteins between the two patient subsets; this is not unexpected because
there is often not a strong correlation between cellular levels and extracellular release of soluble
mediators during culture [34].
The high constitutive mediator release should in our opinion be regarded as only a part of a
more complex communication phenotype with neighboring non-leukemic stromal cells. In contrast,
the cell populations with low constitutive release showed increased abundance proteins involved in or
regulating gene transcription/RNA synthesis/RNA metabolism. A possible hypothesis may be that cells
with high constitutive release have a higher dependency on neighboring AML-supporting stromal cells
than leukemia cells showing low constitutive release. We would emphasize that primary AML cells
have a wide range of secreted biomolecules, which can be useful in classification/prognostication and
as therapeutic targets [11,52,63]. The mediators included in the present study are well-characterized
and are released at detectable levels for most patients. For these reasons they should be regarded
as biologically important in the disease, but they probably represent only a part of the AML cell
secretome that is involved in the bidirectional crosstalk between leukemic and non-leukemic cells in
their common bone marrow microenvironment.
5. Conclusions
We conclude that the high constitutive extracellular release of soluble mediators by primary
human AML cells seems to reflect a complex functional phenotype with regard to communication
between AML cells and their neighboring non-leukemic stromal cells in their common bone marrow
microenvironment. Our proteomic comparison has identified high expression in this patient subset of
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several intracellular molecules that are regarded as possible therapeutic targets in human AML. Dual
targeting of intracellular signaling and extracellular communication should therefore be considered for
these patients.
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